Z17.410 — Hormone receptor positive with human epidermal growth factor receptor 2 positive status
Is Z17.410 billable?
Yes — Z17.410 is billable for FY2027. Z17.410 is a valid, billable ICD-10-CM code at the highest level of specificity in its branch. Z17.410 may be submitted for encounters from October 1, 2026 through September 30, 2027.
Z17.410 at a glance
| Code | Z17.410 |
|---|---|
| Description | Hormone receptor positive with human epidermal growth factor receptor 2 positive status |
| Billable | Yes |
| Code set | ICD-10-CM FY2027 |
| Valid for encounters | October 1, 2026 – September 30, 2027 |
What Medicare edits apply to Z17.410?
The Medicare Code Editor screens inpatient claims before they are grouped. These edits name Z17.410 directly.
CMS will reject this code as the principal diagnosis on an inpatient claim. It describes something other than the condition chiefly responsible for the admission.
Which MS-DRGs does Z17.410 group to?
Z17.410 sits in MDC 23 and helps define the logic of 1 MS-DRG (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.
- 951Other Factors Influencing Health Statusmedical
How is Z17.410 listed in the Alphabetic Index?
These are the routes through the Alphabetic Index that lead to Z17.410. They show the wording a clinician may have documented, which often differs from the Tabular description.
- Status › combined receptor › positive › hormone receptor positive with human epidermal growth factor receptor 2 positive (post)
Inclusion terms
Alternative wording in documentation that is classified to Z17.410.
- HR+ with HER2+
Code first — inherited from Z17
The underlying condition below must be sequenced before Z17.410. Z17.410 describes a manifestation and cannot be the principal or first-listed diagnosis.
How long has Z17.410 existed?
Z17.410 first appears in FY2025.
Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.